Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia

Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent kinase 9 (CDK9) inhibitor LDC526 and its clinically...

Full description

Bibliographic Details
Main Authors: Patricia Johansson, Laura Dierichs, Ludger Klein-Hitpass, Anke K. Bergmann, Michael Möllmann, Sascha Menninger, Peter Habenberger, Bert Klebl, Jens T. Siveke, Ulrich Dührsen, Axel Choidas, Jan Dürig
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/2040620720933761

Internet

https://doi.org/10.1177/2040620720933761

Similar Items